Dyspnea in COVID-associated lung disease

Introduction . Covid-associated lung disease has become one of the leading problems of the COVID-19 pandemic, and early diagnosis of complications is complicated. Assessment of dyspnoea as a significant symptom is important, but its diagnostic ability in this lesion is poorly understood. Aim . To study the features of dyspnoea in COVID-19-associated lung lesions and its diagnostic value. Materials and methods . The study included 134 patients with COVID-19-confirmed pneumonia. Demographic and anthropometric data, subjective condition, dyspnoea severity according to Borg scale, concomitant pathologies, multispiral computed tomography (MSCT) data, arterial blood gas composition, capnometry and spirometry data, as well as disease outcomes (transfer to ICU, support ventilation, fatal outcome) were analysed. Results . Dyspnoea was present in 43.3% of patients. Increased dyspnoea was associated with increased C-reactive protein (CRP), D-dimer, lung tissue damage (MSCT), decreased forced vital capacity (FVC), and increased alveolar-arterial gradient (P(A-a)O 2 ). Dyspnoea correlated with duration of hospitalisation and need for oxygen therapy (OR = 1.307, p = 0.008). 57.4% of patients with hypoxaemia did not complain of dyspnoea, but their outcomes did not differ between patients with dyspnoea and hypoxaemia. 32.2% of patients without hypoxaemia complained of dyspnoea. These patients did not have a significant increase in FGEF by the time of discharge, and it remained lower than in patients without dyspnoea and hypoxaemia. Conclusion . Dyspnoea in COVID-19-associated lung disease is an important symptom correlating with clinical-functional, instrumental and laboratory characteristics of the disease. Comprehensive data analysis is necessary to identify patients requiring further observation.